Arvinas (NASDAQ:ARVN) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a strategy centered on advancing four Phase 1 clinical programs and preparing for ...
Attempts to discern how mutations in the LRRK2 gene contribute to Parkinson’s disease have focused largely on the protein’s role as a kinase. In the January 8 Journal of Neuroscience, researchers led ...
For the first time, researchers have solved the molecular structure of LRRK2, a major risk factor for Parkinson’s and autoimmune diseases. Structural biologists at the University of California, San ...
Leucine-rich repeat kinase 2 (LRRK2) is an autosomal dominant, late-onset familial Parkinson’s disease (PD) gene. LRRK2 consists of several functional domains, including armadillo, ankyrin-like, ...
A hallmark of Parkinson's disease is the buildup of Lewy bodies—misfolded clumps of the protein known as alpha-synuclein.
Future Neurology. 2012;7(2):145-153. Taken together, the present studies do not support a direct biochemical interaction between α-syn and LRRK2, or direct phosphorylation of α-syn by LRRK2, which ...
Hosted on MSN
Scientists report new immune insights and targets into LRRK2 mutations in Parkinson's disease
Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra, a brain region essential for motor ...
An international public-private research consortium has identified and validated a cellular role of a primary Parkinson’s disease drug target, the LRRK2 kinase. This important finding, published in ...
A new treatment for one type of Parkinson's disease may be on the horizon after researchers discovered a "brake" that can halt cell death. The study, led by researchers from Stanford University, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results